COVID-19: Who is at risk of secondary pulmonary fibrosis?

Pulmonary fibrosis can occur secondarily after infection, especially in patients who suffered from severely impaired diffusion capacity during the acute infection.

Symptoms after release are critical

The after-effects of COVID-19 are considerable, especially in people who have a serious illness. Recent data show that pulmonary fibrosis can occur secondarily after infection, especially in patients who suffered from severely impaired diffusion capacity during the acute infection1.

At present, the long-term pulmonary effects of COVID-19 remain speculative. "However, we know that the severity of COVID-19 is related to the symptoms at patient discharge," said Prof. Francesco Blasi of the University of Milan, Italy. In particular, people who fall ill with COVID-19 so severely that admission to an intensive care unit is necessary to seem to be at risk. In the first large series of hospitalized patients with COVID-19 in Wuhan, China, the thoracic CT showed bilateral ground-glass opacity (GGO) in all patients with or without consolidation and with a lower lobe predominance2.

Lung disease after infection also possible

Although the virus is eradicated in those who have recovered from COVID-19, eliminating the cause of lung damage does not in itself preclude the development of progressive, fibrotic irreversible interstitial lung disease. As Prof. Blasi pointed out, early analysis of patients with COVID-19 after discharge from the hospital showed that more than a third of those who recovered, develop fibrotic abnormalities3.

Strong effects on lung diffusion

In addition, 47% of the patients were found to have impaired diffusion capacity for carbon monoxide (30.4% of them with mild illness, 42.4% with pneumonia, and 84.2% with severe pneumonia) and 25% of the patients had reduced total lung capacity3. "Not only diffusion disturbance but also CT changes are observed in patients with severe disease," said Prof. Blasi.

Effects of different therapies tested

For the treatment of pulmonary fibrosis associated with COVID-19, a range of therapies from traditional Chinese medicine to steroids and antifibrotics have been tested. "In our experience, steroids seem to work; they improve physical resilience. But I think that antifibrotics could be another interesting approach," concluded Prof Blasi.

References:
1. Blasi S. COVID-19: Long term impact: the lung and beyond ERS International Virtual Congress 2020, 7-9 Sept.
2. Wang D, et al JAMA 2020;323:1061-1069.
3. Mo X, et al Eur Respir J 2020:55:2001217
.

Esanum is an online network for approved doctors

Esanum is the medical platform on the Internet. Here, doctors have the opportunity to get in touch with a multitude of colleagues and to share interdisciplinary experiences. Discussions include both cases and observations from practice, as well as news and developments from everyday medical practice.

Esanum ist ein Online-Netzwerk für approbierte Ärzte

Esanum ist die Ärzteplattform im Internet. Hier haben Ärzte die Möglichkeit, mit einer Vielzahl von Kollegen in Kontakt zu treten und interdisziplinär Erfahrungen auszutauschen. Diskussionen umfassen sowohl Fälle und Beobachtungen aus der Praxis, als auch Neuigkeiten und Entwicklungen aus dem medizinischen Alltag.

Esanum est un réseau en ligne pour les médecins agréés

Esanum est un réseau social pour les médecins. Rejoignez la communauté et partagez votre expérience avec vos confrères. Actualités santé, comptes-rendus d'études scientifiques et congrès médicaux : retrouvez toute l'actualité de votre spécialité médicale sur esanum.